EA202190802A2 - Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 - Google Patents

Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1

Info

Publication number
EA202190802A2
EA202190802A2 EA202190802A EA202190802A EA202190802A2 EA 202190802 A2 EA202190802 A2 EA 202190802A2 EA 202190802 A EA202190802 A EA 202190802A EA 202190802 A EA202190802 A EA 202190802A EA 202190802 A2 EA202190802 A2 EA 202190802A2
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
receptor agonist
compound
agonist effect
pyrazolopyridine derivatives
Prior art date
Application number
EA202190802A
Other languages
English (en)
Other versions
EA202190802A3 (ru
Inventor
Хитоси Йосино
Сатоси Цутия
Ацуси Мацуо
Цутому Сато
Масахиро Нисимото
Киоко Огури
Хироко Огава
Йосикадзу Нисимура
Йосиюки Фурута
Хиротака Касиваги
Нобуюки Хори
Такума Камон
Такуя Сирайси
Сосин Йосида
Такахиро Кавай
Сатоси Танида
Масахиде Аоки
Original Assignee
Тюгай Сэяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тюгай Сэяку Кабусики Кайся filed Critical Тюгай Сэяку Кабусики Кайся
Publication of EA202190802A2 publication Critical patent/EA202190802A2/ru
Publication of EA202190802A3 publication Critical patent/EA202190802A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Данное изобретение предлагает соединение, имеющее основную структуру, проиллюстрированную формулой (I), в которой индольное кольцо и фрагмент пиразолопиридина соединены через заместитель, его соль или сольват, либо соединения, либо соли соединения, а также профилактическое средство или лекарственное средство для лечения инсулиннезависимого сахарного диабета (диабет типа 2) или ожирения, содержащее такое соединение, соль или сольват в качестве действующего вещества.
EA202190802A 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 EA202190802A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016187605 2016-09-26

Publications (2)

Publication Number Publication Date
EA202190802A2 true EA202190802A2 (ru) 2021-07-30
EA202190802A3 EA202190802A3 (ru) 2021-10-29

Family

ID=61689595

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990518A EA037989B1 (ru) 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
EA202190802A EA202190802A3 (ru) 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201990518A EA037989B1 (ru) 2016-09-26 2017-09-26 Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1

Country Status (35)

Country Link
US (5) US10858356B2 (ru)
EP (3) EP4134367A1 (ru)
JP (4) JP6567778B2 (ru)
KR (1) KR102223227B1 (ru)
CN (1) CN109790161B (ru)
AU (4) AU2017330733B2 (ru)
BR (1) BR112019005322A2 (ru)
CA (1) CA3038479C (ru)
CL (1) CL2019000663A1 (ru)
CO (1) CO2019002595A2 (ru)
CR (1) CR20190149A (ru)
DK (1) DK3517538T3 (ru)
DO (1) DOP2019000074A (ru)
EA (2) EA037989B1 (ru)
EC (1) ECSP19020228A (ru)
FI (1) FI3517538T3 (ru)
HR (1) HRP20240499T1 (ru)
IL (2) IL264945B (ru)
JO (1) JOP20190060A1 (ru)
LT (1) LT3517538T (ru)
MA (1) MA46286A (ru)
MX (2) MX2019003488A (ru)
PE (1) PE20190709A1 (ru)
PH (1) PH12019500659A1 (ru)
PL (1) PL3517538T3 (ru)
PT (1) PT3517538T (ru)
RS (1) RS65398B1 (ru)
SA (1) SA519401409B1 (ru)
SG (1) SG11201901565VA (ru)
SI (1) SI3517538T1 (ru)
TN (1) TN2019000054A1 (ru)
TW (1) TWI753946B (ru)
UA (1) UA125586C2 (ru)
WO (1) WO2018056453A1 (ru)
ZA (1) ZA201901070B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN111527087A (zh) * 2017-11-02 2020-08-11 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新的高活性的吡唑并-哌啶取代的吲哚-2-甲酰胺
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP7360301B2 (ja) 2019-11-08 2023-10-12 Ｋｙｂ株式会社 作動流体供給システム
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
BR112023000932A2 (pt) * 2020-07-20 2023-10-03 Eccogene Shanghai Co Ltd Tetra-hidropirazolo-pirazinil-di-hidroimidazolona ou compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona e métodos de uso dos mesmos
CA3190163A1 (en) * 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116406360A (zh) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 杂环glp-1激动剂
TW202220985A (zh) 2020-09-01 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN116615430A (zh) * 2020-09-07 2023-08-18 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
JPWO2022202864A1 (ru) 2021-03-24 2022-09-29
CA3219984A1 (en) 2021-06-24 2022-12-29 Wenqiang ZHAI Glp-1 receptor agonist and composition and use thereof
WO2023016546A1 (en) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2023138684A1 (en) * 2022-01-24 2023-07-27 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023151574A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
WO2023220109A1 (en) 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 pharmaceutical compositions
WO2023220112A1 (en) 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 tablet compositions
CN116003403B (zh) * 2022-11-20 2024-07-23 药康众拓(北京)医药科技有限公司 一种氘代吲唑类化合物、药物组合物及其应用
WO2024113004A1 (en) * 2022-11-28 2024-06-06 The University Of Melbourne Pharmaceutical combinations and uses thereof
WO2024129676A1 (en) * 2022-12-13 2024-06-20 Eli Lilly And Company Dosage regime of orforglipron for treating a subject with type 2 diabetes (t2d), obesity, or overweight with at least one weight related comorbidity
WO2024137426A1 (en) 2022-12-19 2024-06-27 Eli Lilly And Company Process to make glp1 ra and intermediates therefor
WO2024153070A1 (en) * 2023-01-17 2024-07-25 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
WO2024169952A1 (en) * 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN117447493A (zh) * 2023-12-25 2024-01-26 药康众拓(北京)医药科技有限公司 氘代吲哚嗪类化合物、药物组合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998438A (en) 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
CA2326045C (en) 1998-04-01 2008-12-09 Janssen Pharmaceutica N.V. Pde iv inhibiting pyridine derivatives
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
NZ538223A (en) 2002-08-26 2008-03-28 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
DE10360774A1 (de) 2003-12-23 2005-07-28 Robert Bosch Gmbh Verfahren zur Herstellung eines Brennstoffeinspritzventils und Brennstoffeinspritzventil
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
CN101621931A (zh) * 2006-11-27 2010-01-06 H.隆德贝克有限公司 杂芳基酰胺衍生物
MX2010009752A (es) 2008-03-07 2010-09-30 Transtech Pharma Inc Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
US8962629B2 (en) 2008-06-10 2015-02-24 Abbvie Inc. Tricyclic compounds
AU2010232750B2 (en) * 2009-03-30 2015-10-29 Vtv Therapeutics Llc Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
CN105919998B (zh) * 2009-07-09 2021-08-24 拉夸里亚创药株式会社 用于治疗与异常肠胃运动有关的疾病的酸泵拮抗剂
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
CA2858571C (en) * 2011-12-08 2021-03-16 Research Triangle Institute Composition and method for neuropeptide s receptor (npsr) antagonists
JP6314335B2 (ja) * 2013-02-06 2018-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
CN103086955B (zh) 2013-02-19 2014-10-15 中国医学科学院医药生物技术研究所 3-氨基-4-烷氧亚胺基哌啶的制备方法
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
EP2993174A1 (en) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Also Published As

Publication number Publication date
AU2017330733A1 (en) 2019-03-14
SI3517538T1 (sl) 2024-05-31
AU2020223687B2 (en) 2022-04-14
NZ751725A (en) 2021-03-26
US11814381B2 (en) 2023-11-14
US10858356B2 (en) 2020-12-08
PT3517538T (pt) 2024-04-09
US20240246971A1 (en) 2024-07-25
AU2022205222A1 (en) 2022-08-04
EP4134367A1 (en) 2023-02-15
EP4349840A2 (en) 2024-04-10
ECSP19020228A (es) 2019-06-30
BR112019005322A2 (pt) 2019-07-02
MX2019003488A (es) 2019-12-16
CO2019002595A2 (es) 2019-03-29
HRP20240499T1 (hr) 2024-07-05
EP4349840A3 (en) 2024-07-10
IL264945A (en) 2019-05-30
CA3038479C (en) 2021-06-22
JP6567778B2 (ja) 2019-08-28
JP6957564B2 (ja) 2021-11-02
TN2019000054A1 (en) 2020-07-15
DOP2019000074A (es) 2019-05-31
LT3517538T (lt) 2024-05-10
FI3517538T3 (fi) 2024-05-20
SA519401409B1 (ar) 2022-04-07
US20230382912A1 (en) 2023-11-30
JPWO2018056453A1 (ja) 2019-07-11
KR20190039591A (ko) 2019-04-12
AU2020223687A1 (en) 2020-09-10
DK3517538T3 (da) 2024-03-25
EP3517538A1 (en) 2019-07-31
AU2017330733B2 (en) 2020-05-28
IL287166A (en) 2021-12-01
CN109790161B (zh) 2022-03-11
PH12019500659A1 (en) 2019-12-16
JP7280929B2 (ja) 2023-05-24
RS65398B1 (sr) 2024-04-30
US20210017176A1 (en) 2021-01-21
JP2022003087A (ja) 2022-01-11
EA037989B1 (ru) 2021-06-21
AU2022205222B2 (en) 2024-04-04
JP2023100963A (ja) 2023-07-19
JP2019203015A (ja) 2019-11-28
US20240262824A1 (en) 2024-08-08
TWI753946B (zh) 2022-02-01
WO2018056453A1 (ja) 2018-03-29
EP3517538A4 (en) 2020-06-10
PE20190709A1 (es) 2019-05-17
CN109790161A (zh) 2019-05-21
CL2019000663A1 (es) 2019-07-26
JOP20190060A1 (ar) 2019-03-26
CA3038479A1 (en) 2018-03-29
EP3517538B1 (en) 2024-03-13
SG11201901565VA (en) 2019-03-28
PL3517538T3 (pl) 2024-06-10
MA46286A (fr) 2019-07-31
ZA201901070B (en) 2021-06-30
UA125586C2 (uk) 2022-04-27
KR102223227B1 (ko) 2021-03-08
AU2024201884A1 (en) 2024-04-11
MX2022004071A (es) 2022-05-03
IL264945B (en) 2021-10-31
CR20190149A (es) 2019-08-27
EA202190802A3 (ru) 2021-10-29
EA201990518A1 (ru) 2019-12-30
US20190225604A1 (en) 2019-07-25
TW201827426A (zh) 2018-08-01

Similar Documents

Publication Publication Date Title
EA202190802A2 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
PE20191143A1 (es) Nuevos compuestos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201992679A1 (ru) N-замещенные индольные производные
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201692298A1 (ru) Производные карбоксамидов
MX2018008671A (es) Composicion para incrementar la expresion de pgc-1alfa.
TW201613914A (en) 2-acylaminothiazole derivative or salt thereof
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
BR112022008647A2 (pt) Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo
EA201891691A1 (ru) Асимметричные бензолсульфонилмочевины и их применение в медицине
TH1901001721A (th) อนุพันธ์ไพราโซโลไพริดีนที่มีผลที่มีผลของglp-1รีเซพเตอร์อะโกนิสต์
EA202190707A1 (ru) Ингибиторы о-гликопротеин-2-ацетамидо-2-деокси-3-d-глюкопиранозидазы
TH1801004568A (th) อนุพันธ์เฮเทอโรไซคลิคซัลโฟนาไมด์และยาซึ่งมีสารดังกล่าว
AR110330A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
PH12016502247A1 (en) Carboxamide derivatives
TH133841B (th) อนุพันธ์เบนโซซาซีน ไพริดิลชนิดใหม่, องค์ประกอบเภสัชกรรมที่ประกอบด้วย อนุพันธ์ดังกล่าวและการใช้สารเหล่านั้น
TH166320B (th) สารอนุพันธ์ไพราซีน